Abstract
Gp41 is regarded as an attractive target for development of HIV-1 entry inhibitors since it mediates the fusion process of HIV- 1 entry into the target cell through the six-helix bundle (6-HB) formation between its N-heptad repeat (NHR) and C-heptad repeat (CHR). Any chemical entity that disrupts the six-helix bundle formation may inhibit the fusion process, thereby blocking HIV-1 entry into the target cells. A brief review of discovering small molecule inhibitors targeting gp41 is presented here, including the development of assay methods, current known small molecule inhibitors and their binding mode studies. Lessons learned and challenges remained in view of blocking protein-protein interaction between NHR and CHR are also discussed.
Keywords: gp41, HIV-1, assay, small molecule inhibitor, protein-protein interaction
Current Pharmaceutical Design
Title:Discovery of Small Molecule Fusion Inhibitors Targeting HIV-1 gp41
Volume: 19 Issue: 10
Author(s): Guangyan Zhou and Shidong Chu
Affiliation:
Keywords: gp41, HIV-1, assay, small molecule inhibitor, protein-protein interaction
Abstract: Gp41 is regarded as an attractive target for development of HIV-1 entry inhibitors since it mediates the fusion process of HIV- 1 entry into the target cell through the six-helix bundle (6-HB) formation between its N-heptad repeat (NHR) and C-heptad repeat (CHR). Any chemical entity that disrupts the six-helix bundle formation may inhibit the fusion process, thereby blocking HIV-1 entry into the target cells. A brief review of discovering small molecule inhibitors targeting gp41 is presented here, including the development of assay methods, current known small molecule inhibitors and their binding mode studies. Lessons learned and challenges remained in view of blocking protein-protein interaction between NHR and CHR are also discussed.
Export Options
About this article
Cite this article as:
Zhou Guangyan and Chu Shidong, Discovery of Small Molecule Fusion Inhibitors Targeting HIV-1 gp41, Current Pharmaceutical Design 2013; 19 (10) . https://dx.doi.org/10.2174/1381612811319100006
DOI https://dx.doi.org/10.2174/1381612811319100006 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenomics of Nicotine Dependence and Impact on Smoking Cessation
Current Pharmacogenomics HER2 Targeted Therapies for Cancer and the Gastrointestinal Tract
Current Drug Targets Targeting miRNAs for Drug Discovery: A New Paradigm
Current Molecular Medicine Functional Nanoplatforms for Enhancement of Chemotherapeutic Index
Anti-Cancer Agents in Medicinal Chemistry Progress of Individualized Chemotherapy for Gastric Carcinoma Under the Guidance of Genetic Testing
Current Medicinal Chemistry Editorial (Thematic Issue: Investigate the Functions of Chemicals Through Heterogeneous Network of Chemicals and Proteins)
Combinatorial Chemistry & High Throughput Screening Editorial (Thematic Issue: Improving Cancer Clinical Research and Trials with Hispanic Populations: Training and Outreach Efforts Between Moffitt Cancer Center and the Ponce School of Medicine)
Reviews on Recent Clinical Trials Editorial (Thematic Issue: Targeting Anti-Cancer Agents and Cancer Treatments)
Anti-Cancer Agents in Medicinal Chemistry Stem Cell Therapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Crosstalk between IGF-1R and other Tumor Promoting Pathways
Current Pharmaceutical Design Expression and Function of PPARs in Cancer Stem Cells
Current Stem Cell Research & Therapy Epigenetic Alterations of the Wnt/β -Catenin Pathway in Human Disease
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Antibodies
Current Molecular Medicine Metal Ion Complexes with Pyrazoles, Aziridines and Diaziridines – Synthesis and Biological Activity
Current Medicinal Chemistry MET As a Potential Target for the Treatment of Upper Gastrointestinal Cancers: Characterization of Novel c-Met Inhibitors from Bench to Bedside
Current Medicinal Chemistry Nanotechnological Strategies to Improve Water Solubility of Commercially Available Drugs
Current Nanomedicine Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry Clinical Importance of Assessment of Type 2 Diabetes Mellitus with Visceral Obesity. A Japanese Perspective
Current Diabetes Reviews Effects of Plants and Isolates of Celastraceae Family on Cancer Pathways
Anti-Cancer Agents in Medicinal Chemistry Anti-EGFR Therapy: Strategies in Head and Neck Squamous Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery